Insys Therapeutics Inc (NASDAQ:INSY) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $5.04 and last traded at $5.12, with a volume of 35132 shares traded. The stock had previously closed at $5.32.
A number of equities research analysts recently issued reports on the company. ValuEngine upgraded Insys Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 15th. Zacks Investment Research downgraded Insys Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. Piper Jaffray Companies set a $4.00 price objective on Insys Therapeutics and gave the stock a “sell” rating in a research report on Saturday, August 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $10.00 price objective on shares of Insys Therapeutics in a research report on Friday, August 10th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $7.67.
The stock has a market capitalization of $381.75 million, a PE ratio of -10.57 and a beta of 1.58.
Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings data on Monday, November 5th. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.08). Insys Therapeutics had a negative return on equity of 266.60% and a negative net margin of 128.88%. The business had revenue of $18.30 million during the quarter, compared to analysts’ expectations of $24.05 million. During the same quarter last year, the business posted ($2.30) EPS. The company’s quarterly revenue was down 40.4% on a year-over-year basis. Sell-side analysts expect that Insys Therapeutics Inc will post -1.32 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in Insys Therapeutics in the third quarter valued at $113,000. Tower Research Capital LLC TRC bought a new position in Insys Therapeutics in the second quarter valued at $131,000. Creative Planning bought a new position in Insys Therapeutics in the third quarter valued at $153,000. MetLife Investment Advisors LLC bought a new position in Insys Therapeutics in the third quarter valued at $223,000. Finally, BNP Paribas Arbitrage SA increased its stake in Insys Therapeutics by 47.4% in the second quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock valued at $225,000 after acquiring an additional 10,001 shares during the last quarter. 17.22% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2018/12/08/insys-therapeutics-insy-hits-new-12-month-low-at-5-04.html.
About Insys Therapeutics (NASDAQ:INSY)
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
See Also: Why is the conference call important?
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.